Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct 29;1(4):237-243.
doi: 10.1016/j.adro.2016.10.008. eCollection 2016 Oct-Dec.

Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma

Kiri A Sandler  1 , Darlene Veruttipong  1 , Vatche G Agopian  2 , Richard S Finn  3 , Johnny C Hong  2 , Fady M Kaldas  2 , Saeed Sadeghi  3 , Ronald W Busuttil  2 , Percy Lee  1
Affiliations

Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma

Kiri A Sandler et al. Adv Radiat Oncol. .

Abstract

Objectives: We report single-institution clinical efficacy and safety outcomes for patients with unresectable locally advanced cholangiocarcinoma who were treated with stereotactic body radiation therapy (SBRT) and a subset of patients who received neoadjuvant SBRT and chemotherapy as part of an orthotopic liver transplantation (OLT) protocol.

Methods and materials: From October 2008 to June 2015, 31 consecutive patients with unresectable extrahepatic (n = 25) or intrahepatic (n = 6) cholangiocarcinoma were treated with SBRT and retrospectively analyzed. Four patients underwent liver transplantation, and 1 underwent resection. SBRT was delivered in 5 fractions with a median dose of 40 Gy. Toxicity was scored using the Common Terminology Criteria for Adverse Events Version 4.0. Overall survival (OS), time to progression, and local control were estimated using the Kaplan-Meier method.

Results: The median follow-up time was 11.5 months. The 1- and 2-year OS rates were 59% and 33%, respectively, with a median survival of 15.7 months. The 1- and 2-year freedom from progression was 67% and 34%, respectively. Median time to progression was 16.8 months. Nine patients had local failure. The actuarial 1- and 2-year local control rates were 78% and 47%, respectively. Among patients who also had OLT, the median OS was 31.3 months. Twenty-four patients (77%) experienced some form of acute grade 1-2 toxicity, most commonly fatigue or pain. Five patients (16%) experienced grade ≥3 toxicity.

Conclusions: SBRT is a promising option for patients with unresectable or recurrent cholangiocarcinoma either as a component of neoadjuvant therapy prior to OLT or as part of definitive therapy for patients who are unresectable and not eligible for transplantation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier curve demonstrating time to local tumor progression.
Figure 2
Figure 2
Kaplan-Meier curve demonstrating overall survival, stratified by surgical and nonsurgical patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. DeOliveira M.L., Cunningham S.C., Cameron J.L. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245:755–762. - PMC - PubMed
    1. Welzel T.M., McGlynn K.A., Hsing A.W., O'Brien T.R., Pfieffer R.M. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006;98:873–875. - PubMed
    1. Vauthey J.N., Blumgart L.H. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis. 1994;14:109–114. - PubMed
    1. Farley D.R., Weaver A.L., Nagorney D.M. “Natural history” of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc. 1995;70:425–429. - PubMed
    1. Grove M.K., Hermann R.E., Vogt D.P., Broughan T.A. Role of radiation after operative palliation in cancer of the proximal bile ducts. Am J Surg. 1991;161:454–458. - PubMed

LinkOut - more resources